"Placenta Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiogenic protein belonging to the Vascular Endothelial Growth Factor family of growth factors originally isolated and cloned from human placental cDNA library. There are four isoforms of PLGF 1-4 which result from alternative splicing. Placenta Growth Factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer.
| Descriptor ID |
D000072483
|
| MeSH Number(s) |
D12.644.276.100.800.100 D12.776.780.551
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Placenta Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Placenta Growth Factor".
This graph shows the total number of publications written about "Placenta Growth Factor" by people in this website by year, and whether "Placenta Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Placenta Growth Factor" by people in Profiles.
-
Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024 09 13; 13(18).
-
Placental growth factor at 24-28?weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial. Acta Obstet Gynecol Scand. 2024 Nov; 103(11):2273-2280.
-
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA. 2023 02 21; 329(7):542-550.
-
Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management. Pregnancy Hypertens. 2023 Mar; 31:32-37.
-
Usefulness of angiogenic factors in prenatal counseling of late-onset fetal growth-restricted and small-for-gestational-age gestations: a prospective observational study. Arch Gynecol Obstet. 2023 11; 308(5):1485-1495.
-
Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study. Am J Obstet Gynecol MFM. 2023 01; 5(1):100760.
-
sFlt-1 to PlGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study. J Obstet Gynaecol. 2022 Oct; 42(7):2840-2845.
-
First-trimester screening for pre-eclampsia and small for gestational age: A comparison of the gaussian and Fetal Medicine Foundation algorithms. Int J Gynaecol Obstet. 2023 Jan; 160(1):150-160.
-
Cohort study on the differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke. J Cereb Blood Flow Metab. 2022 10; 42(10):1827-1839.
-
Shared risk factors for COVID-19 and preeclampsia in the first trimester: An observational study. Acta Obstet Gynecol Scand. 2022 07; 101(7):803-808.